Medmen is on the forefront of cannabis cultivation and uses all the latest technology to ensure the marijuana plans are up to the highest standard. Alyssa Julya Smith visits a LA grow facility where MedMen's VP of Corporate Communications Daniel Yi explains how the process works. Yi explains that marijuana cultivations is much like other urban farms, using sterilized and controlled environments to ensure successful growth. He explains that LED lighting is key to urban cannabis farms and all the different variables, including light, temperature and water can be controlled through computers. Yi explains that plants like light, not heat, so LED bulbs are perfect to ensure optimal growing conditions. The marijuana plants at MedMen are also pesticide free and everyone has to wear special outfits to ensure nothing from the outside world contaminate the plants.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More